SAN DIEGO, Jan. 27 /PRNewswire/ -- Fructose-1,6-bisphosphatase (FBPase) is a key regulatory enzyme in the gluconeogenic pathway and a target for the development of novel diabetes therapeutics focused on lowering hepatic glucose production in type 2 diabetics. By offering co-crystallization structure services for this target, ActiveSight is making it possible for client companies to easily apply the principles of rational structure-based design to their proprietary lead compounds.
"FBPase is the first of a suite of important diabetes target proteins we will be introducing this year," stated Les Tari, PhD, ActiveSight's Director of Structural Biology. "Our goal is to accelerate our customers' drug development programs by putting key structural information within their reach."
ActiveSight is building a portfolio of "Ready-to-Go" key drug targets. Human FBPase is the second target to be introduced. The first portfolio protein was human Hsp90, an emerging oncology target.
ActiveSight(TM), a structural biology company in San Diego, California, provides outsourcing solutions to the pharmaceutical and biotechnology industries. ActiveSight is a division of Rigaku/MSC. Visit us at http://www.active-sight.com/.
CONTACT: Joy Silen of ActiveSight, +1-858-455-6870, ext. 105